Sorry, you need to enable JavaScript to visit this website.

A Randomized Clinical Trial of Bococizumab ( RN316) in Patients at High Risk for Heart Disease (SPIRE-LL Study)

A 52-Week Phase 3 Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the
Efficacy, Safety and Tolerability of PF-04950615 in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events

Category & Conditions: Cardiovasular Diseases and Conditions
Medicine: Bococizumab (PF-04950615) Identifier (NCT): NCT02100514
Protocol ID: B1481045
Open Plain Language Summary Result: Click here